Foghorn Therapeutics Inc. (FHTX) Misses Q2 EPS by 9c
Tweet
Share
E-mailGet Alerts FHTX Hot Sheet
Join SI Premium – FREE
Foghorn Therapeutics Inc. (NASDAQ: FHTX) reported Q2 EPS of ($0.66), $0.09 worse than the analyst estimate of ($0.57). Revenue for the quarter came in at $4.49 million versus the consensus estimate of $8.69 million.
For earnings history and earnings-related data on Foghorn Therapeutics Inc. (FHTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan Upgrades Aviva Plc (AV/:LN) (AIVAF) to Overweight
- Southland Holdings (SLND) Misses Q2 EPS by 122c
- Mannatech (MTEX) Tops Q2 EPS by 53c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
